Evommune, Inc. Common Stock (EVMN)
19.69
+0.08 (0.41%)
NYSE · Last Trade: Dec 12th, 3:01 AM EST
Detailed Quote
| Previous Close | 19.61 |
|---|---|
| Open | 19.96 |
| Bid | 18.71 |
| Ask | 21.50 |
| Day's Range | 19.45 - 20.54 |
| 52 Week Range | 16.70 - 24.03 |
| Volume | 265,185 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 96,782 |
Chart
News & Press Releases
Evommune, Inc. (NYSE: EVMN) (the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update.
By Evommune, Inc. · Via Business Wire · December 11, 2025
